Purpose To investigate 1-year clinical outcome and complication rates following Descemet membrane endothelial keratoplasty (DMEK) with sulfur hexafluoride 20% (SF620%) anterior chamber tamponade compared with conventionally used 100% air for primary graft attachment during DMEK surgery.
Methods Records of 1112 consecutive DMEKs were reviewed retrospectively and grouped by anterior chamber tamponade used during DMEK surgery (SF620% vs 100% air). Outcome measures included intraocular pressure (IOP), best spectacle-corrected visual acuity (BSCVA), endothelial cell density (ECD) and central corneal thickness (CCT) at 1, 3, 6 and 12 months after DMEK surgery. Complication rates were assessed, including intraoperative and postoperative complications, and graft detachment rate requiring rebubbling.
Results A total of 854 cases were included in this study. In 105 cases (12.3%), DMEK was performed with SF620%, and in 749 cases (87.7%) 100% air was used for anterior chamber tamponade. Outcome results for IOP, BSCVA, ECD and CCT at all follow-up time points were comparable for both anterior chamber tamponade groups without statistical significant differences (p≥0.05), but graft detachment rate requiring rebubbling was significantly lower in the SF620% group (p<0.001).
Conclusion Whereas SF620% anterior chamber tamponade does not seem to negatively affect the clinical outcome of DMEK surgery within the first postoperative year, use of SF620% significantly reduces the rate of rebubblings.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors Conception and design: FS and CC. Data collection, evaluation and analyses: FS, PE, KS, SS, SS, BOB and LMH. Preparation, review and approval of the manuscript: all authors.
Funding German Research Foundation FOR 2240 “(Lymph) Angiogenesis And Cellular Immunity in Inflammatory Diseases of the Eye” to CC and LMH (http://www.for2240.de), EU COST BM1302 “Joining Forces in Corneal Regeneration” to BB and CC (http://www.biocornea.eu).
Competing interests None declared.
Ethics approval The study was approved by the local Institutional Review Board (14–373) and was conducted in adherence to the tenets of the Declaration of Helsinki.
Provenance and peer review Not commissioned; externally peer reviewed.